Senseonics Holdings (SENS)


Market Price (11/18/2026): $10.18 | Market Cap: $557.7 MilSector: Health Care | Industry: Life Sciences Tools & Services

Senseonics Holdings (SENS)


Market Price (11/18/2026): $10.18
Market Cap: $557.7 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 105%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Remote Patient Monitoring, Show more.

Weak multi-year price returns
3Y Excs Rtn is -71%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -121 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -201%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 20%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -188%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -190%

Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 64%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23%

Key risks
SENS key risks include [1] its high risk of financial distress and ongoing shareholder dilution, Show more.

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 105%
1 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Remote Patient Monitoring, Show more.
2 Weak multi-year price returns
3Y Excs Rtn is -71%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -121 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -201%
4 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 20%
5 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -188%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -190%
6 Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 64%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23%
8 Key risks
SENS key risks include [1] its high risk of financial distress and ongoing shareholder dilution, Show more.

SENS in ETFs

Weight = SENS's share of each fund

VTI0.00%
ITOT0.00%
IWM0.01%
IWO0.03%
SCHA0.01%
VTWO0.01%
SCHB0.00%
DFAC0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/17/2026

Nov 17: down 6.8% in one day (S&P 500 down 1.0%)
The stock declined without specific negative company news. The broader market also fell, dragged by slower retail sales.

Up 47.3% from its Oct 22 low to Nov 16, down 6.8% since (S&P 500 down 3.1%)
The stock rose significantly due to company-specific developments, including its innovation roadmap and strong financial results. Key gains occurred October 27 with the Freedom CGM study initiation and November 9 with strong third-quarter earnings.

Nov 10: up 2.3% the day after its Nov 9 earnings report (S&P 500 down 0.4%)
The stock gained further after Senseonics Holdings reported its third-quarter 2026 financial results, including strong revenue growth and increased full-year guidance. This occurred despite a decline in the S&P 500 that day.

Show more
Prices as of 11/17/2026

Nov 17: down 6.8% in one day (S&P 500 down 1.0%)
The stock declined without specific negative company news. The broader market also fell, dragged by slower retail sales.

Up 47.3% from its Oct 22 low to Nov 16, down 6.8% since (S&P 500 down 3.1%)
The stock rose significantly due to company-specific developments, including its innovation roadmap and strong financial results. Key gains occurred October 27 with the Freedom CGM study initiation and November 9 with strong third-quarter earnings.

Nov 10: up 2.3% the day after its Nov 9 earnings report (S&P 500 down 0.4%)
The stock gained further after Senseonics Holdings reported its third-quarter 2026 financial results, including strong revenue growth and increased full-year guidance. This occurred despite a decline in the S&P 500 that day.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 102.0% change in SENS stock from 7/31/2026 to 11/17/2026 was primarily driven by a 96.6% change in the company's P/S Multiple.
(LTM values as of)731202611172026Change
Stock Price ($)5.0310.16102.0%
Change Contribution By: 
Total Revenues ($ Mil)416047.4%
P/S Multiple5.711.196.6%
Shares Outstanding (Mil)4666-30.3%
Cumulative Contribution102.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/17/2026
ReturnCorrelation
SENS102.0% 
Market (SPY)-1.7%42.5%
Sector (XLV)14.4%30.0%

Fundamental Drivers

The 53.7% change in SENS stock from 4/30/2026 to 11/17/2026 was primarily driven by a 70.2% change in the company's Total Revenues ($ Mil).
(LTM values as of)430202611172026Change
Stock Price ($)6.6110.1653.7%
Change Contribution By: 
Total Revenues ($ Mil)356070.2%
P/S Multiple8.511.131.2%
Shares Outstanding (Mil)4566-31.2%
Cumulative Contribution53.7%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/17/2026
ReturnCorrelation
SENS53.7% 
Market (SPY)2.4%35.1%
Sector (XLV)27.9%22.6%

Fundamental Drivers

The 44.1% change in SENS stock from 10/31/2025 to 11/17/2026 was primarily driven by a 135.7% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511172026Change
Stock Price ($)7.0510.1644.1%
Change Contribution By: 
Total Revenues ($ Mil)2560135.7%
P/S Multiple11.311.1-1.1%
Shares Outstanding (Mil)4166-38.1%
Cumulative Contribution44.1%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/17/2026
ReturnCorrelation
SENS44.1% 
Market (SPY)8.5%40.0%
Sector (XLV)30.6%25.5%

Fundamental Drivers

The 2.8% change in SENS stock from 10/31/2023 to 11/17/2026 was primarily driven by a 225.2% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202311172026Change
Stock Price ($)9.8810.162.8%
Change Contribution By: 
Total Revenues ($ Mil)1860225.2%
P/S Multiple15.211.1-26.7%
Shares Outstanding (Mil)2866-56.9%
Cumulative Contribution2.8%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/17/2026
ReturnCorrelation
SENS2.8% 
Market (SPY)81.6%27.6%
Sector (XLV)56.4%17.3%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
SENS Return206%-61%-45%-8%-47%84%-42%
Peers Return34%-24%-12%2%-8%-13%-27%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
SENS Win Rate42%33%50%25%25%55% 
Peers Win Rate62%46%42%50%50%39% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
SENS Max Drawdown-68%-75%-61%-65%-80%-42% 
Peers Max Drawdown-23%-48%-49%-36%-36%-42% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: DXCM, ABT, MMED, PODD, TNDM. See SENS Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/17/2026 (YTD)

How Low Can It Go

EventSENSS&P 500
2024 Yen Carry Trade Unwind
  % Loss-15.5%-7.8%
  % Gain to Breakeven18.3%8.5%
  Time to Breakeven126 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-46.3%-9.5%
  % Gain to Breakeven86.2%10.5%
  Time to Breakeven452 days24 days
2023 SVB Regional Banking Crisis
  % Loss-48.9%-6.7%
  % Gain to Breakeven95.8%7.1%
  Time to Breakeven653 days31 days
2020 COVID-19 Crash
  % Loss-64.3%-33.7%
  % Gain to Breakeven179.9%50.9%
  Time to Breakeven287 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-41.1%-19.2%
  % Gain to Breakeven69.9%23.8%
  Time to Breakeven789 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-64.4%-3.7%
  % Gain to Breakeven180.7%3.9%
  Time to Breakeven383 days6 days

Compare to DXCM, ABT, MMED, PODD, TNDM

In The Past

Senseonics Holdings's stock fell -15.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 18.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventSENSS&P 500
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-46.3%-9.5%
  % Gain to Breakeven86.2%10.5%
  Time to Breakeven452 days24 days
2023 SVB Regional Banking Crisis
  % Loss-48.9%-6.7%
  % Gain to Breakeven95.8%7.1%
  Time to Breakeven653 days31 days
2020 COVID-19 Crash
  % Loss-64.3%-33.7%
  % Gain to Breakeven179.9%50.9%
  Time to Breakeven287 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-41.1%-19.2%
  % Gain to Breakeven69.9%23.8%
  Time to Breakeven789 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-64.4%-3.7%
  % Gain to Breakeven180.7%3.9%
  Time to Breakeven383 days6 days

Compare to DXCM, ABT, MMED, PODD, TNDM

In The Past

Senseonics Holdings's stock fell -15.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 18.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Senseonics Holdings (SENS)

Senseonics Holdings, Inc. (SENS) is a medical technology company focused on improving diabetes management. It specializes in the development and commercialization of continuous glucose monitoring (CGM) systems designed to help people with diabetes track their glucose levels accurately and conveniently.

The company's flagship products are the Eversense and Eversense XL CGM systems. These innovative systems feature a unique implantable sensor, placed just under the skin, which continuously measures glucose levels for an extended period, lasting up to six months. The system is completed by a removable, rechargeable smart transmitter worn on the arm that communicates with the sensor, and a convenient mobile application providing real-time glucose data for proactive diabetes monitoring and management.

Senseonics primarily serves individuals with diabetes and the healthcare providers who support them. The company reaches its customers and patients through a network of distributors and strategic fulfillment partners across significant global markets, including the United States, Europe, the Middle East, and Africa.

AI Analysis | Feedback

1. Senseonics is like **Dexcom**, but for a continuous glucose monitor that's **implanted under the skin and works for up to six months**.

2. Think of it as an **Apple Watch for diabetes**, but instead of wearing it, a tiny glucose sensor is **implanted and lasts for half a year**.

3. It's a medical device company similar to **Medtronic**, but focused on a unique **long-term implantable continuous glucose monitor**.

AI Analysis | Feedback

  • Eversense: An implantable continuous glucose monitoring (CGM) system that measures glucose levels via an under-the-skin sensor, a smart transmitter, and a mobile app.
  • Eversense XL: An implantable continuous glucose monitoring (CGM) system that measures glucose levels via an under-the-skin sensor, a smart transmitter, and a mobile app.

AI Analysis | Feedback

Senseonics Holdings (SENS) sells primarily to other companies, specifically through a network of distributors and strategic fulfillment partners.

The major customer and global commercial partner for Senseonics Holdings is:

  • Ascensia Diabetes Care

Ascensia Diabetes Care is a private company and is the exclusive global commercial partner responsible for the sales and distribution of Senseonics' Eversense continuous glucose monitoring (CGM) systems.

AI Analysis | Feedback

null

AI Analysis | Feedback

Timothy T. Goodnow, PhD, President & CEO

Timothy T. Goodnow joined the Senseonics Board of Directors in December 2010 and was named President & CEO in March 2011. He has been instrumental in commercializing the Eversense continuous glucose monitoring (CGM) systems in Europe and the U.S.. Prior to Senseonics, Dr. Goodnow served as Vice President of Technical Operations at Abbott Diabetes Care and held executive positions at TheraSense, Verax Biomedical, Dade Behring, and Baxter Healthcare. TheraSense, where he held an executive position, was acquired by Abbott. He earned his PhD and Bachelor of Science degree in Chemistry at the University of Miami.

Frederick T. Sullivan, Chief Financial Officer, Secretary and Treasurer

Frederick T. Sullivan was appointed Chief Financial Officer of Senseonics Holdings, Inc. effective September 1, 2022. Prior to this role, he served as the Company's Vice President of Finance since October 2020. Mr. Sullivan's experience before joining Senseonics includes serving as a Principal at Hike Financial and Chief Financial Officer of RoosterBio. Inc.. He also held positions as Treasurer and Controller within Senseonics and progressively advanced through various finance roles at the company. He is a certified public accountant and holds a Masters of Business Administration from the University of Maryland - Robert H. Smith School of Business and a Bachelor of Science in accounting from Salisbury University - Perdue School of Business.

Mukul Jain, PhD, Chief Operating Officer

Mukul Jain is the Chief Operating Officer at Senseonics, responsible for overseeing Quality, Regulatory, Product Development, and Global Operations, which includes manufacturing and supply chain. Before joining Senseonics, Dr. Jain spent 13 years at Medtronic, where he worked on active implantable devices in the CRDM and Neuromodulation sectors. He managed the development of Neurostimulator systems in spinal cord stimulation and sacral nerve stimulation and also worked at Medtronic Energy and Components Center developing critical components for implantable devices.

Francine R. Kaufman, M.D., Chief Medical Officer

As Chief Medical Officer, Dr. Francine R. Kaufman focuses on driving the innovation platform and clinical value proposition of the Eversense CGM system. She is a leading endocrinologist with nearly 40 years of experience in diabetes care. Prior to her role at Senseonics, Dr. Kaufman served as Chief Medical Officer and Vice President of Global Clinical, Regulatory and Medical Affairs at Medtronic Diabetes from 2009 to January 2019.

Brian Hansen, Chief Commercial Officer

Brian Hansen was appointed as Senseonics' Chief Commercial Officer in January 2026, having previously served as Ascensia's President of CGM since February 2024. He possesses over 30 years of commercial experience across the medical device, life sciences, and diagnostic industries. Before his time at Ascensia, Mr. Hansen was Executive Vice President and Chief Commercial Officer at Tandem Diabetes Care starting in January 2016, and held key leadership positions at Adaptive Biotechnologies, Novartis, Gen-Probe, and Fisher Scientific.

AI Analysis | Feedback

The key risks for Senseonics Holdings (SENS) are primarily centered around its financial viability, the adoption and commercialization of its continuous glucose monitoring (CGM) systems, and intense competition in the medical technology sector.

  1. Financial Viability and Going Concern: Senseonics Holdings faces significant financial distress, with the company itself having expressed "substantial doubt about its ability to continue as a going concern" due to recurring losses and uncertainty regarding its liquidity. The company experiences high sales and marketing expenses and other operating costs, contributing to ongoing negative free cash flow and significant share dilution. Reports indicate a limited cash runway, estimated to be between 9 and 13 months without additional capital raises.
  2. Adoption and Commercialization Challenges: A major risk is the adoption and retention of patients for its Eversense CGM systems, particularly the Eversense 365. Despite the product's unique long-term wear, numerous barriers hinder adoption, including the necessity of a medical procedure for insertion and prior authorization, which can deter potential patients. The company has acknowledged an anemic user base growth, hampered by these adoption challenges. Furthermore, Senseonics is in the process of re-taking full commercial control of its products from its distribution partner, Ascensia Diabetes Care, a transition that requires building new sales and marketing infrastructure and securing additional funding, introducing execution risks.
  3. Intense Competitive Landscape: Senseonics operates in a highly competitive global CGM market where its products compete against kits from other manufacturers. While Eversense offers advantages like extended duration and implantability, competitors often provide easier-to-start solutions that do not require an office visit or a medical procedure, posing a significant challenge to customer acquisition and retention. Despite the overall growth of the CGM market, Senseonics remains a relatively small player.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable market for Senseonics Holdings' continuous glucose monitoring (CGCGM) systems, such as Eversense, encompasses significant global and U.S. markets.

Globally, the continuous glucose monitoring market was valued at approximately USD 13.86 billion in 2025 and is projected to grow to about USD 15.52 billion in 2026. Another estimate indicates the global market size was USD 13.4 billion in 2025 and is projected to reach USD 15.5 billion in 2026. This market is anticipated to expand further, with projections reaching USD 33.61 billion by 2034 or USD 41.4 billion by 2033.

In the United States, the continuous glucose monitoring market is substantial. It was estimated at USD 6.28 billion in 2025 and is projected to reach USD 7.43 billion in 2026. The U.S. market is expected to continue its growth trajectory, potentially reaching USD 17.16 billion by 2031. North America held a significant share of the global market, accounting for 44.6% in 2025. Senseonics Holdings itself indicates that the U.S. total addressable market is more than $20 billion, with the market remaining significantly underpenetrated.

For Europe, Senseonics noted that the European approval for Eversense 365 expands its total addressable market by over 30 million patients living with diabetes in the European Union.

AI Analysis | Feedback

Senseonics Holdings, Inc. (SENS) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

  1. Increased Adoption and Reimbursement of Eversense 365 (E365): A primary driver of revenue growth is the continued and expanding adoption of the Eversense 365 continuous glucose monitoring (CGM) system in the U.S. and internationally. The company expects full-year 2025 global net revenue to be approximately $34-38 million, primarily driven by the rollout of Eversense 365 to U.S. patients. This growth is supported by positive Centers for Medicare & Medicaid Services (CMS) reimbursement for the one-year CGM, effective January 1, 2025, which is considered a significant milestone for patient access. Senseonics aims to approximately double its global patient base in 2025.
  2. Enhanced Commercialization Strategy and Direct-to-Consumer (DTC) Marketing: Senseonics is transitioning its commercialization and distribution efforts from Ascensia to an in-house model, which is anticipated to lead to higher revenue and improved gross margins. This strategic shift involves taking over the full sales and marketing infrastructure, including in Europe. Aggressive direct-to-consumer marketing campaigns are actively generating leads and contributing to substantial new patient growth in the U.S., with a 103% increase in new patients in Q4 2025 compared to Q4 2024. The company is also scaling its Eon Care Network, comprising nurses who perform insertion procedures, as a crucial growth driver.
  3. International Market Expansion and Regulatory Approvals: Growth is also expected from the expansion of Eversense 365 into new international markets. The company completed its CE Mark application for Eversense 365 in the European Union in Q1 2025, with a launch anticipated in the second half of 2025. The rollout of Eversense 365 outside the United States is a significant factor in the company's financial outlook for 2025 and 2026, with Europe projected to contribute approximately 20% of the full-year 2026 revenue.
  4. Integration with Automated Insulin Delivery (AID) Systems: Collaborations to integrate Eversense 365 with automated insulin delivery (AID) systems are expected to drive adoption. Senseonics has a collaboration agreement with Sequel to integrate Eversense 365 with its twiist™ AID system, with a launch expected in Q3 2025. The company has noted encouraging uptake of Eversense 365 in combination with the twiist system. Additionally, a strategic partnership with Beta Bionics to integrate Eversense 365 with the iLet® Bionic Pancreas was announced in September 2026.
  5. Development and Launch of New Products, such as the Gemini Sensor: Future revenue growth is also tied to the development and anticipated launch of next-generation products. Senseonics secured Investigational Device Exemption (IDE) approval from the FDA to commence a pivotal trial for its self-powered battery-enabled Gemini sensor and has already enrolled the first patients. The 510(k) submission for the Gemini CGM is targeted for Q1 2027, with a launch expected shortly thereafter.

AI Analysis | Feedback

Share Issuance

  • Senseonics Holdings conducted a reverse stock split at a ratio of one-for-twenty, which became effective on October 17, 2025, reducing the number of outstanding shares from approximately 816 million to about 41 million.
  • The company raised over $20 million in gross proceeds in 2024 and an additional $27.0 million in early 2025 through equity offerings to strengthen its balance sheet.
  • In October 2026, directors of Senseonics Holdings, Inc. received common stock in lieu of quarterly cash retainer fees; for example, Edward Fiorentino acquired 1,418 shares, Douglas S. Prince received 1,515 shares, and Steven Edelman was issued 1,292 shares.

Inbound Investments

  • In August 2020, Senseonics entered a strategic collaboration and commercialization agreement with Ascensia Diabetes Care, granting Ascensia exclusive worldwide commercial rights to Senseonics products, with Ascensia investing several million dollars in sales and promotion.
  • In September 2025, Senseonics and Ascensia signed a memorandum of understanding to transfer the commercial operations related to Eversense back to Senseonics, effective January 1, 2026.

Capital Expenditures

  • Senseonics Holdings reported capital expenditures of -$2.17 million over the last 12 months, as of October 9, 2026.
  • Quarterly capital expenditures for 2025 included $394,000 in Q4 and $164,000 in Q3, while for 2026, they were $111,000 in Q1 and $217,000 in Q2.
  • Research and development expenses, crucial for product development, decreased by $9.5 million in 2025 to $31.6 million, largely due to the completion of Eversense 365 clinical trials; however, higher investment in the Gemini and Freedom development programs contributed to R&D expenses of $11.6 million in Q2 2026.

Better Bets vs. Senseonics Holdings (SENS)

Peer Outperformance in Life Sciences Tools & Services

SENS has trailed 62% of its 109 Life Sciences Tools & Services peers over 5Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that SENS has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
90%
of 125 industry peers · 72.2% return
3Y
54%
of 115 industry peers · -13.6% return
5Y
38%
of 109 industry peers · -85.9% return
No Life Sciences Tools & Services peer with a comparable growth profile has beaten SENS by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is SENS's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 16.4%84.2%198.3% CAH 522% · MCK 400% · COR 198%
Health Care Services 20 31.2%20.2%12.4% RDNT 150% · HIMS 116% · DGX 91%
Managed Health Care 8 76.8%-0.8%0.8% OSCR 155% · HQY 56% · ELV 9%
Health Care Facilities 26 17.8%19.4%-9.2% THC 258% · NHC 231% · EHC 186%
Health Care Equipment 49 -1.7%4.4%-20.2% GKOS 390% · UFPT 359% · TMDX 293%
Health Care Supplies 11 24.0%1.1%-40.5% LNTH 248% · HAE 108% · MMSI 25%
Pharmaceuticals 60 -18.7%1.7%-45.2% LQDA 1123% · KNSA 638% · XERS 586%
Life Sciences Tools & Services ← 110 -22.4%-26.1%-76.2% AXGN 400% · MEDP 187% · NTRA 156%
Health Care Technology 23 -23.5%-59.7%-83.4% VEEV -8% · DOCS -55%
Biotechnology 370 -33.7%-38.5%-83.9% ELVN 1378% · TRVI 1175% · DNTH 1141%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

SENSDXCMABTMMEDPODDTNDMMedian
NameSenseoni.DexCom Abbott L.Minimed Insulet Tandem D. 
Mkt Price10.1881.98104.3017.79144.0017.6049.89
Mkt Cap0.730.7180.95.010.01.27.5
Rev LTM605,10448,2293,2223,1891,0763,206
Op Inc LTM-1211,2246,647-188588-101244
FCF LTM-1141,7326,757-316233-7181
FCF 3Y Avg-781,2116,720-286-74286
CFO LTM-1132,2098,855-105509-15247
CFO 3Y Avg-771,6558,901-457-6457

Growth & Margins

SENSDXCMABTMMEDPODDTNDMMedian
NameSenseoni.DexCom Abbott L.Minimed Insulet Tandem D. 
Rev Chg LTM104.8%13.0%10.0%-26.5%6.8%13.0%
Rev Chg 3Y Avg49.4%14.5%6.5%-27.0%11.8%14.5%
Rev Chg Q141.6%11.2%14.5%16.6%19.2%13.8%15.5%
QoQ Delta Rev Chg LTM23.6%2.7%3.5%3.9%4.4%3.3%3.7%
Op Inc Chg LTM-95.5%57.4%-13.8%-34.6%42.9%34.6%
Op Inc Chg 3Y Avg-25.1%35.1%4.3%-66.9%20.5%20.5%
Op Mgn LTM-201.0%24.0%13.8%-5.8%18.4%-9.3%4.0%
Op Mgn 3Y Avg-253.6%19.0%15.9%-17.1%-17.2%15.9%
QoQ Delta Op Mgn LTM22.2%1.1%-2.0%0.2%1.5%2.3%1.3%
CFO/Rev LTM-188.4%43.3%18.4%-3.3%16.0%-1.4%7.3%
CFO/Rev 3Y Avg-217.8%35.6%20.1%-17.9%-0.5%17.9%
FCF/Rev LTM-190.0%33.9%14.0%-9.8%7.3%-6.6%0.3%
FCF/Rev 3Y Avg-223.1%25.9%15.2%-11.5%-7.7%11.5%

Valuation

SENSDXCMABTMMEDPODDTNDMMedian
NameSenseoni.DexCom Abbott L.Minimed Insulet Tandem D. 
Mkt Cap0.730.7180.95.010.01.27.5
P/S11.26.03.81.63.11.13.4
P/Op Inc-5.525.127.2-26.617.0-12.25.7
P/EBIT-5.724.123.9-26.616.4-33.25.3
P/E-5.531.038.5-15.123.3-24.98.9
P/CFO-5.913.920.4-47.619.6-83.94.0
Total Yield-18.3%3.2%5.0%-6.6%4.3%-4.1%-0.5%
Dividend Yield0.0%0.0%2.4%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-20.3%4.2%3.4%-1.9%-5.9%1.9%
D/E0.10.00.20.00.10.60.1
Net D/E-0.1-0.00.1-0.00.00.20.0

Returns

SENSDXCMABTMMEDPODDTNDMMedian
NameSenseoni.DexCom Abbott L.Minimed Insulet Tandem D. 
1M Rtn31.0%-4.7%-0.6%1.7%2.1%8.4%1.9%
3M Rtn17.1%-8.5%-6.9%-8.1%-2.7%-25.8%-7.5%
6M Rtn83.8%22.4%19.0%63.4%-6.9%27.0%24.7%
12M Rtn72.5%40.2%-17.8%-3.8%-56.1%-4.0%-3.9%
3Y Rtn-13.4%-21.9%11.6%-3.8%-17.3%-1.1%-8.6%
1M Excs Rtn30.6%-1.1%3.8%3.6%5.0%11.1%4.4%
3M Excs Rtn15.5%-5.0%-4.5%-8.2%-1.2%-21.1%-4.8%
6M Excs Rtn82.9%21.6%18.1%62.5%-7.7%26.1%23.8%
12M Excs Rtn52.5%31.1%-28.2%-13.9%-66.8%-15.9%-14.9%
3Y Excs Rtn-70.8%-80.8%-49.5%-71.8%-74.5%-46.9%-71.3%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Diabetes products and services3522221614
Total3522221614


Net Income by Segment
$ Mil202520242023
Diabetes products and services-69-79-60
Total-69-79-60


Price Behavior

Price Behavior
Market Price$10.16 
Market Cap ($ Bil)0.7 
First Trading Date03/18/2016 
Distance from 52W High-6.8% 
   50 Days200 Days
DMA Price$9.21$7.35
DMA Trendupup
Distance from DMA10.3%38.3%
 3M1YR
Volatility77.0%82.1%
Downside Capture221.71245.58
Upside Capture366.20285.14
Correlation (S&P 500)52.8%38.6%
SENS Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta3.692.532.902.082.271.60
Up Beta-3.30-1.07-0.060.041.461.46
Down Beta3.174.454.282.092.451.18
Up Capture433%295%645%521%513%775%
Bmk +ve Days12182862130427
Stock +ve Days9223562132349
Down Capture395%199%106%161%161%113%
Bmk -ve Days10253664121325
Stock -ve Days13212962115396

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with SENS
SENS62.6%82.1%0.94-
Sector ETF (XLV)24.2%16.9%1.1025.5%
Equity (SPY)10.2%13.8%0.4538.6%
Gold (GLD)-6.3%28.8%-0.2319.2%
Commodities (DBC)31.6%21.3%1.18-6.3%
Real Estate (VNQ)10.0%14.2%0.4219.4%
Bitcoin (BTCUSD)-31.4%43.7%-0.7524.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with SENS
SENS-33.0%91.1%-0.05-
Sector ETF (XLV)8.6%15.4%0.3624.3%
Equity (SPY)10.9%17.3%0.4635.9%
Gold (GLD)15.5%19.2%0.659.8%
Commodities (DBC)7.1%19.6%0.256.8%
Real Estate (VNQ)0.9%19.0%-0.0624.2%
Bitcoin (BTCUSD)-0.6%51.4%0.1721.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with SENS
SENS-14.5%93.8%0.23-
Sector ETF (XLV)12.4%16.8%0.6121.4%
Equity (SPY)14.9%18.0%0.7029.3%
Gold (GLD)11.2%16.6%0.556.1%
Commodities (DBC)7.4%18.2%0.3210.2%
Real Estate (VNQ)5.8%20.7%0.2421.8%
Bitcoin (BTCUSD)57.2%66.3%0.9710.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity4.7 Mil
Short Interest: % Change Since 10152026-2.7%
Average Daily Volume0.6 Mil
Days-to-Cover Short Interest7.8 days
Basic Shares Quantity65.7 Mil
Short % of Basic Shares7.2%

Earnings Returns History

Updated 11/18/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/9/20262.3%11.2% 
8/6/202636.3%50.1%87.0%
5/7/2026-6.2%8.6%33.0%
3/2/2026-18.1%-24.2%-20.0%
1/12/2026-1.5%7.5%14.7%
10/6/2025-16.9%-25.8%-40.8%
8/6/2025-4.9%-0.9%-6.0%
5/8/2025-15.2%-25.4%-28.1%
...
SUMMARY STATS   
# Positive101510
# Negative171216
Median Positive10.7%9.1%27.7%
Median Negative-10.5%-19.5%-17.3%
Max Positive36.3%50.1%131.6%
Max Negative-19.3%-32.9%-40.8%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/9/20262.3%11.2% 
8/6/202636.3%50.1%87.0%
5/7/2026-6.2%8.6%33.0%
3/2/2026-18.1%-24.2%-20.0%
1/12/2026-1.5%7.5%14.7%
10/6/2025-16.9%-25.8%-40.8%
8/6/2025-4.9%-0.9%-6.0%
5/8/2025-15.2%-25.4%-28.1%
3/3/2025-19.3%-32.9%-23.6%
1/13/2025-3.5%9.1%41.5%
11/7/2024-12.5%-19.6%-18.1%
8/8/2024-6.8%1.7%-16.6%
5/13/202410.3%5.6%-10.0%
2/29/2024-10.5%-15.8%-25.4%
11/9/20232.0%16.4%25.1%
8/10/2023-8.5%-30.0%-15.7%
5/9/202323.9%9.7%13.7%
3/15/2023-10.5%-19.5%-37.2%
11/8/2022-14.2%4.2%-6.7%
8/9/202211.4%16.8%-14.6%
5/10/2022-16.1%-3.2%-13.7%
3/1/202210.7%-1.7%7.9%
11/9/2021-0.5%0.0%-22.7%
8/11/202110.7%4.0%30.3%
5/13/202112.3%22.8%131.6%
3/8/20211.6%27.8%4.8%
11/9/2020-7.9%-13.2%-7.0%
SUMMARY STATS   
# Positive101510
# Negative171216
Median Positive10.7%9.1%27.7%
Median Negative-10.5%-19.5%-17.3%
Max Positive36.3%50.1%131.6%
Max Negative-19.3%-32.9%-40.8%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/09/202610-Q
06/30/202608/06/202610-Q
03/31/202605/07/202610-Q
12/31/202503/02/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/08/202510-Q
12/31/202403/03/202510-K
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202405/13/202410-Q
12/31/202303/01/202410-K
09/30/202311/09/202310-Q
06/30/202308/10/202310-Q
03/31/202305/09/202310-Q
12/31/202203/16/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/09/202610-Q
06/30/202608/06/202610-Q
03/31/202605/07/202610-Q
12/31/202503/02/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/08/202510-Q
12/31/202403/03/202510-K
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202405/13/202410-Q
12/31/202303/01/202410-K
09/30/202311/09/202310-Q
06/30/202308/10/202310-Q
03/31/202305/09/202310-Q
12/31/202203/16/202310-K
09/30/202211/08/202210-Q
06/30/202208/09/202210-Q
03/31/202205/10/202210-Q
12/31/202103/01/202210-K
09/30/202111/09/202110-Q
06/30/202108/09/202110-Q
03/31/202105/13/202110-Q
12/31/202003/05/202110-K
09/30/202011/09/202010-Q
06/30/202008/10/202010-Q
03/31/202006/09/202010-Q
12/31/201903/16/202010-K

Recent Forward Guidance

Updated 11/10/2026

Latest: Q3 2026 Earnings Reported 11/9/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 EON Care InsertersReported 120    
2026 Global Net RevenueReported68.00 Mil69.00 Mil70.00 Mil7.8% RaisedGuidance: 64.00 Mil for 2026
2026 Revenue GrowthReported93.0%95.5%98.0%   
2026 Revenue Outside the United States ShareReported 0.15    
2026 Gross MarginReported60.0%60.0%  0.5%RaisedGuidance: 59.5% for 2026


Prior: Q2 2026 Earnings Reported 8/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported62.00 Mil64.00 Mil66.00 Mil3.2% RaisedGuidance: 62.00 Mil for 2026
2026 Gross ProfitCalculated35.96 Mil38.08 Mil40.26 Mil  Rev x Gross Margin
2026 Gross MarginReported58.0%59.5%61.0% 3.0%RaisedGuidance: 56.5% for 2026

Insider Activity

Updated 11/16/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Roeder, Douglas ADirectBuy1116202610.3217,041175,8601,957,828Form
2Roeder, Douglas ADirectBuy82020268.9813,953125,3001,537,298Form
3Roeder, Douglas ADirectBuy51320265.5622,686126,134804,171Form
4Roeder, Douglas ADirectBuy31620265.7317,500100,275686,059Form
5Goodnow, Timothy TPresident and CEODirectBuy31620265.7917,22599,7333,770,697Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Roeder, Douglas ADirectBuy1116202610.3217,041175,8601,957,828Form
2Roeder, Douglas ADirectBuy82020268.9813,953125,3001,537,298Form
3Roeder, Douglas ADirectBuy51320265.5622,686126,134804,171Form
4Roeder, Douglas ADirectBuy31620265.7317,500100,275686,059Form
5Goodnow, Timothy TPresident and CEODirectBuy31620265.7917,22599,7333,770,697Form
6Steven, EdelmanDirectBuy111320256.5510,00065,500489,337Form
7Roeder, Douglas ADirectBuy111020255.8315,00087,450581,408Form
8Sullivan, Frederick TChief Financial OfficerDirectBuy111020255.885,41531,840923,325Form
9Goodnow, Timothy TPresident and CEODirectBuy111020255.8717,210101,0233,880,569Form

Investor Activity (13F)

Updated Nov 18, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Sessa Capital IM, L.P.$11.8 Mil0.2%31New13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Sessa Capital IM, L.P.$11.8 Mil0.2%31New13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Sessa Capital IM, L.P.$11.8 Mil0.2%31New13F
Core Cache Last Updated: 11/17/2026